Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,478Revenue $M1,212Net Margin (%)-36.7Z-Score10.7
Enterprise Value $M19,676EPS $-2.0Operating Margin %-74.5F-Score4
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-80.5Higher ROA y-yY
Price/Book16.410-y EBITDA Growth Rate %0Quick Ratio3.8Cash flow > EarningsY
Price/Sales19.85-y EBITDA Growth Rate %0Current Ratio3.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-19.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-32.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M236ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 88.9112%Add 5.89%11,628,500
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 88.9112%New holding, 10000 sh.10,000
VRTXJohn Burbank 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 88.9112%New holding, 2872 sh.2,872
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 88.9128%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 88.9112%Add 19%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 88.9121%Add 140.58%5,990,000
VRTXDaniel Loeb 2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)
$ 88.9193%Sold Out0
VRTXJohn Burbank 2012-12-31 Sold Out -0.38%$38.88 - $59.42
($46.08)
$ 88.9193%Sold Out0
VRTXDaniel Loeb 2012-09-30 Add0.22%$48.38 - $59.07
($53.5)
$ 88.9166%Add 40%700,000
VRTXJohn Burbank 2012-09-30 Reduce-0.09%$48.38 - $59.07
($53.5)
$ 88.9166%Reduce -25%150,000
VRTXGeorge Soros 2012-09-30 Sold Out -0.09%$48.38 - $59.07
($53.5)
$ 88.9166%Sold Out0
VRTXJoel Greenblatt 2012-09-30 Sold Out -0.08%$48.38 - $59.07
($53.5)
$ 88.9166%Sold Out0
VRTXDaniel Loeb 2012-06-30 Buy 0.85%$35.75 - $65.62
($50.92)
$ 88.9175%New holding, 500000 sh.500,000
VRTXJohn Burbank 2012-06-30 Buy 0.38%$35.75 - $65.62
($50.92)
$ 88.9175%New holding, 200000 sh.200,000
VRTXJoel Greenblatt 2012-06-30 Buy 0.08%$35.75 - $65.62
($50.92)
$ 88.9175%New holding, 20025 sh.20,025
VRTXJohn Hussman 2012-06-30 Sold Out -0.93%$35.75 - $65.62
($50.92)
$ 88.9175%Sold Out0
VRTXGeorge Soros 2012-06-30 Reduce-0.05%$35.75 - $65.62
($50.92)
$ 88.9175%Reduce -44%112,000
VRTXJean-Marie Eveillard 2012-06-30 Sold Out -0.02%$35.75 - $65.62
($50.92)
$ 88.9175%Sold Out0
VRTXGeorge Soros 2012-03-31 Buy 0.12%$32.2 - $42.94
($35.95)
$ 88.91147%New holding, 200000 sh.200,000
VRTXJean-Marie Eveillard 2012-03-31 Buy 0.02%$32.2 - $42.94
($35.95)
$ 88.91147%New holding, 110000 sh.110,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRTX Vanguard Health Care Fund 2014-06-3011,807,50052.9+1.54%
VRTX John Burbank 2014-03-312,87200.01New Buy
VRTX George Soros 2014-03-3110,00000.01New Buy
Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Riley Wayne JosephDirector 2014-07-15Sell4,800$96.65-4.8view
Horton Kenneth LEVP & Chief Legal Officer 2014-07-01Sell30,134$95.22-3.37view
ULLIAN ELAINEDirector 2014-07-01Sell5,000$95.21-3.36view
Riley Wayne JosephDirector 2014-06-24Sell15,000$98.03-6.14view
Pace Megan ESVP, Corp. Communications 2014-06-24Sell12,734$98.03-6.14view
Sachdev AmitSVP, Global Gov. Strategy 2014-06-24Sell42,250$98.03-6.14view
MUELLER PETEREVP, Global R&D, CSO 2014-06-16Sell7,500$68.3134.69view
ULLIAN ELAINEDirector 2014-06-09Sell2,500$7522.68view
Pace Megan ESVP, Corp. Communications 2014-05-15Sell369$65.6640.13view
MUELLER PETEREVP, Global R&D, CSO 2014-05-14Sell7,500$67.4536.41view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
    Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
    Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
    Vertex Could Climb On New Drug, VX-222 Success Apr 21 2012 
    Achillion Will Surge If New Drug Is Successful Apr 21 2012 
    Columbia Management Fourth Quarter Letter with Comments on SWK, AGCO, CE, MCP, VRTX, DOLE, F, HAS, A Apr 10 2012 
    Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
    4 Pharmaceuticals with Long and Short Opportunities Feb 28 2012 


    More From Other Websites
    Vertex Pharmaceuticals Posts Wider Q2 Loss, Maintains View Jul 30 2014
    Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and... Jul 29 2014
    Vertex Pharma posts bigger 2Q loss Jul 29 2014
    Vertex Pharma posts bigger 2Q loss Jul 29 2014
    Vertex Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today Jul 29 2014
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition Jul 29 2014
    4:10 pm Vertex Pharm misses by $0.07, beats on revs; reaffirms FY14 non-GAAP rev guidance Jul 29 2014
    Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and... Jul 29 2014
    Q2 2014 Vertex Pharmaceuticals Incorporated Earnings Release - After Market Close Jul 29 2014
    Will Vertex Pharmaceuticals (VRTX) Loss be Below Estimates? Jul 28 2014
    Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings? Jul 28 2014
    MONDAY DEADLINE: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex... Jul 25 2014
    Vertex Is Poised For An Earnings Breakout Jul 23 2014
    Why a Trial for a Vertex Cystic Fibrosis Drug Combo Sent Mixed Signals Jul 23 2014
    INVESTOR ALERT: Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated Announced by Law... Jul 23 2014
    SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 In Vertex... Jul 22 2014
    Sales Tax Compliance Concerns Loom Large, But Does Automation Help? Jul 18 2014
    [$$] Costly Vertex Drug Is Denied, and Medicaid Patients Sue Jul 17 2014
    Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data Jul 16 2014
    SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Vertex... Jul 15 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide